Unlock the power of AI with Our Diagnostic Solutions

Our relentless pursuit of scientific excellence propels us toward groundbreaking discoveries that transform lives and shape the future of diagnostics.

Pioneering transformation of Diagnostic Research

The current age of scientific advancement has resulted in novel innovations in various domains of Diagnostics. We at Sensaheal work on Omics based and sensor-backed diagnostics for quick and accurate disease prediction

Robust R&D Team

Our multidisciplinary team consists of Omics Scientists, Electronics Engineers, Computer Scientists, Oncologists and Clinical Doctors.

Published/Patented Studies

Our solutions are based on robust research works which are published in per reviewed journals and protected by IPRs.

AI & Data Science

Our data and results are reproducible and managed with the highest ethical integrity on secured Cloud backup.

New Insights

AI-driven data analytics to bring new insights for point-of-care (POC) solutions for rapid, accurate, and cost-effective diagnostics

Why Sensaheal solutions?

We love to discover, explore, and work on the intricacy of human health. We analyze, code, and develop new solutions. We test our products on real clinical samples. Time-series analysis and signal processing of bio signals backed by AI is our expertise. We enjoy this journey while making a difference in diagnostic research. We at Sensaheal is the future of non-invasive, accurate and affordable diagnostics. 

Accelerate Time To Value

SensaHeal accelerates diagnostic research time-to-value by combining advanced sensor technology, AI-driven analytics, and non-invasive diagnostic platforms for rapid biomarker discovery and validation.

Future-Proof R&D Informatics

SensaHeal’s solution provides future-proof R&D informatics by leveraging scalable AI-driven analytics and adaptable sensor technologies to evolve with emerging diagnostic needs and advancements.

Backed by R&D Outcomes

SensaHeal’s solutions are backed by a robust R&D foundation, integrating advanced BioSignal analytics, AI-driven insights, and cutting-edge sensor technologies validated through rigorous clinical research and multidisciplinary expertise.

Clinically Tested

SensaHeal's solutions are rigorously tested on real-world clinical datasets, ensuring high accuracy, reliability, and applicability across diverse diagnostic scenarios.

Trusted solutions with real data analytics

Trusted by clinicians and researchers, backed by cutting-edge MedTech R&D.

Sense of smell: Structural, functional, mechanistic advancements and challenges in human olfactory research

Current Neuropharmacology, DOI:10.2174/1570159X17666181206095626

DeepOlf: Deep neural network based architecture for predicting odorants and their interacting Olfactory Receptors

IEEE/ACM Transactions on Computational Biology and Bioinformatics, DOI:10.1109/TCBB.2020.3002154

XGBoost odor prediction model: finding the structure-odor relationship of odorant molecules using the extreme gradient boosting algorithm

Journal of Biomolecular Structure and Dynamics, DOI:10.1080/07391102.2023.2258415

Differences in olfactory functioning: The role of personality and gender

Journal of Sensory Studies, DOI:10.1111/joss.12907

Identification of novel dysregulated key genes in Breast cancer through high throughput ChIP-Seq data analysis

Scientific Reports, DOI:10.1038/s41598-017-03534-x

Unravelling the role of long non-coding RNA-LINC01087 in breast cancer

Non-coding RNA Research, DOI:10.1016/j.ncrna.2019.12.002

PGC1 alpha coactivates ERG fusion to drive antioxidant target genes under metabolic stress

Communications Biology, DOI:10.1038/s42003-022-03385-x

An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma

Plos one, DOI:10.1371/journal.pone.0223554

An entropy-based classification of breast cancerous genes using microarray data

Neural Computing and Applications, DOI:10.1007/s00521-018-3864-8

Comparative modeling and structure based drug repurposing of PAX2 transcription factor for targeting acquired chemoresistance in pancreatic ductal adenocarcinoma

Journal of Biomolecular Structure and Dynamics, DOI:10.1080/07391102.2020.1742793

Understanding the mechanism of cell death in gemcitabine resistant pancreatic ductal adenocarcinoma: A systems biology approach

Current Genomics, DOI:10.2174/1389202920666191025102726

In silico identification of therapeutic compounds against microRNA targets in drug-resistant pancreatic ductal adenocarcinoma

Journal of Biomolecular Structure and Dynamics, DOI:10.1080/07391102.2020.1782262